NEW HAVEN, Conn., May 23, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company’s programs in HIV, HCV and serious bacterial infections at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008 at 11:30 a.m. at The New York Palace Hotel.
